Dyadic Applied BioSolutions Partners with IBT Bioservices for Commercial Distribution of Recombinant Protein Products
ByAinvest
Monday, Mar 16, 2026 7:22 am ET1min read
DYAI--
Dyadic Applied BioSolutions has partnered with IBT Bioservices to commercialize recombinant protein products. The initial products include DNase I and transferrin for research-use-only applications. This agreement supports Dyadic's transition to commercial product sales and enables its products to reach the market through established global distribution channels. Dyadic believes this agreement reflects progress in advancing from platform development to commercial execution and supports its long-term objective of translating its technology and manufacturing capabilities into scalable revenue opportunities.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet